ERBB2 and cancer: However, population-based studies have reported that detection of early (asymptomatic) cardiotoxicity in the adjuvant setting places patients at risk of not completing their intended anti-HER2 targeted therapy, and thus increasing their risk of cancer recurrence and death (19).